

A

Agnholt, J. and Kaltoft, K. (2001) Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. *Cytokine*, 15, 212-222.

Aitman, T.J., Dong, R., Vyse, T.J., Norsworthy, P.J., Johnson, M.D., Smith, J., Mangion, J., Robertson-Lowe, C., Marshall, A.J., Petretto, E., *et al.* (2006) Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. *Nature*, 439, 851-855.

Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen recognition and innate immunity. *Cell*, 124, 783-801.

Ansari, N., Abdulla, J., Zayyani, N., Brahmi, U., Taha, S. and Satir, A.A. (2006) Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? *J Clin Pathol*, 59, 1066-1072.

Anwar, N., Lovestone, S., Cheetham, M.E., Levy, R. and Powell, J.F. (1993) Apolipoprotein E-epsilon 4 allele and Alzheimer's disease. *Lancet*, 342, 1308-1309.

Arvidson, N.G., Larsen, A., Aaseth, J. and Larsson, A. (2007) Short-term effects of the TNF α antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. *Scandinavian Journal of Clinical and Laboratory Investigation*, 67, 337 - 342.

B

Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A. and Rutgeerts, P. (2003) Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. *N Engl J Med*, 348, 601-608.

Barnes, B.J., Kellum, M.J., Field, A.E. and Pitha, P.M. (2002) Multiple Regulatory Domains of IRF-5 Control Activation, Cellular Localization, and Induction of Chemokines That Mediate Recruitment of T Lymphocytes. *Mol. Cell. Biol.*, 22, 5721-5740.

Barnes, B.J., Moore, P.A. and Pitha, P.M. (2001) Virus-specific Activation of a Novel Interferon Regulatory Factor, IRF-5, Results in the Induction of Distinct Interferon alpha Genes. *J. Biol. Chem.*, 276, 23382-23390.

Beckmann, J.S., Estivill, X. and Antonarakis, S.E. (2007) Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. *Nat Rev Genet*, 8, 639-646.

Bejerano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W.J., Mattick, J.S. and Haussler, D. (2004) Ultraconserved Elements in the Human Genome. *Science*, 304, 1321-1325.

Bell, P.A., Chaturvedi, S., Gelfand, C.A., Huang, C.Y., Kochersperger, M., Kopla, R., Modica, F., Pohl, M., Varde, S., Zhao, R., *et al.* (2002) SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. *Biotechniques*, Suppl, 70-72, 74, 76-77.\par.

Bill, N., Xiangjun, G., Richard, W., David, C., Mehrdad, Y., Xiangdong, L., Vanya, P., Mark van, O., Christopher, I.A. and Katherine, A.S. (2005) A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. *Gastroenterology*, 128, 260-269.

Binder, V. (2004) Epidemiology of IBD during the twentieth century: an integrated view. *Best Pract Res Clin Gastroenterol.*, 18, 463-479.

Black, R.A. (2002) Tumor necrosis factor-alpha converting enzyme. *Int J Biochem Cell Biol.*, 34, 1-5.

Buckland, P.R. (2003) Polymorphically duplicated genes: their relevance to phenotypic variation in humans. *Ann Med.*, 35, 308-315.

C

Calkins, B.M. (1989) A meta-analysis of the role of smoking in inflammatory bowel disease. *Dig Dis Sci.*, 34, 1841-1854.

Calkins, B.M. and Mendeloff, A.I. (1986) EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE. *Epidemiol Rev*, 8, 60-91.

Cardon, L.R. and Bell, J.I. (2001) Association study designs for complex diseases. *Nat Rev Genet*, 2, 91-99.

Carlson, C.S., Eberle, M.A., Rieder, M.J., Yi, Q., Kruglyak, L. and Nickerson, D.A. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. *Am J Hum Genet.*, 74, 106-120.

Cavanaugh, J. (2001) International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. *Am J Hum Genet.*, 68, 1165-1171.

Cavanaugh, J.A., Callen, D.F., Wilson, S.R., Stanford, P.M., Sraml, M.E., Gorska, M., Crawford, J., Whitmore, S.A., Shlegel, C., Foote, S., *et al.* (1998) Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. *Annals of Human Genetics*, 62, 291-298.

Chamberlin, W.M. and Naser, S.A. (2006) Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses. *Med Sci Monit.*, 12, RA27-33.

Chaudhary, R. and Ghosh, S. (2005) Prediction of response to infliximab in Crohn's disease. *Dig Liver Dis.*, 37, 559-563.

Collins, F.S., Brooks, L.D. and Chakravarti, A. (1998) A DNA Polymorphism Discovery Resource for Research on Human Genetic Variation. *Genome Res.*, 8, 1229-1231.

Colombel, J.-F., Loftus, E., Tremaine, W., Egan, L., Harmsen, S., Schleck, C., Zinsmeister, A. and Sandborn, W. (2003) The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. *Gastroenterology*, 126, 19-31.

Cooper, G.S., Miller, F.W. and Pandey, J.P. (1999) The role of genetic factors in autoimmune disease: implications for environmental research. *Environ Health Perspect.*, 107, 693-700.

Corrao, G., Tragnone, A., Caprilli, R., Trallori, G., Papi, C., Andreoi, A., Di Paolo, M., Riegler, G., Rigo, G.-P., Ferrà, O., *et al.* (1998) Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. *Int. J. Epidemiol.*, 27, 397-404.

Cottone, M., Rosselli, M., Orlando, A., Oliva, L., Puleo, A., Cappello, M., Traina, M., Tonelli, F. and Pagliaro, L. (1994) Smoking habits and recurrence in Crohn's disease. *Gastroenterology.*, 106, 643-648.

Curran, M.E., Lau, K.F., Hampe, J., Schreiber, S., Bridger, S., Macpherson, A.J., Cardon, L.R., Sakul, H., Harris, T.J., Stokkers, P., *et al.* (1998) Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. *Gastroenterology.*, 115, 1066-1071.

D

D'Haens, G., Geboes, K., Peeters, M., Baert, F., Ectors, N. and Rutgeerts, P. (1997) Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. *Am J Gastroenterol.*, 92, 1275-1279.

Dalziel, T.K. (1989) Thomas Kennedy Dalziel 1861-1924. Chronic interstitial enteritis. *Dis Colon Rectum.*, 32, 1076-1078.

Danese, S., Sans, M., Scaldaferri, F., Sgambato, A., Rutella, S., Cittadini, A., Pique, J.M., Panes, J., Katz, J.A., Gasbarrini, A., *et al.* (2006) TNF- α Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease. *J Immunol*, 176, 2617-2624.

Danese, S., Semeraro, S., Papa, A., Roberto, I., Scaldaferri, F., Fedeli, G., Gasbarrini, G. and Gasbarrini, A. (2005) Extraintestinal manifestations in inflammatory bowel disease. *World J Gastroenterol.*, 11, 7227-7236.

Dawson, E., Chen, Y., Hunt, S., Smink, L.J., Hunt, A., Rice, K., Livingston, S., Bumpstead, S., Bruskiwich, R., Sham, P., *et al.* (2001) A SNP Resource for Human Chromosome 22: Extracting Dense Clusters of SNPs From the Genomic Sequence. *Genome Res.*, 11, 170-178.

Dionne, S., Hiscott, J., D'Agata, I., Duhaime, A. and Seidman, E.G. (1997) Quantitative PCR Analysis of TNF- α and IL-1 β mRNA Levels in Pediatric IBD Mucosal Biopsies. *Digestive Diseases and Sciences*, 42, 1557-1566.

Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhart, A.H., Abraham, C., Regueiro, M., Griffiths, A., *et al.* (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene *Science.*, 314, 1461-1463.

E

Economou, M., Trikalinos, T.A., Loizou, K.T., Tsianos, E.V. and Ioannidis, J.P.A. (2004) Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis. *The American Journal of Gastroenterology*, 99, 2393-2404.

Esters, N., Vermeire, S., Joossens, S., Noman, M., Louis, E., Belaiche, J., Vos, M., Gossuin, A., Pescatore, P., Fiasse, R., *et al.* (2002) Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. *The American Journal of Gastroenterology*, 97, 1458-1462.

F

Fedorak, R.N. (2004) Is it time to re-classify Crohn's disease? *Best Practice & Research Clinical Gastroenterology*, 18, 99-106.

Fellermann, K., Stange, D.E., Schaeffeler, E., Schmalzl, H., Wehkamp, J., Bevins, C.L., Reinisch, W., Teml, A., Schwab, M., Lichter, P., *et al.* (2006) A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon. *Am J Hum Genet*, 79, 439-448.

Feuk, L., Carson, A.R. and Scherer, S.W. (2006) Structural variation in the human genome. *Nat Rev Genet*, 7, 85-97.

Fielding, J.F. (1988) Crohn's disease and Dalziel's syndrome. A history. *J Clin Gastroenterol.*, 10, 279-285.

Franchimont, D., Vermeire, S., El Housni, H., Pierik, M., Van Steen, K., Gustot, T., Quertinmont, E., Abramowicz, M., Van Gossum, A., Deviere, J., *et al.* (2004) Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. *Gut*, 53, 987-992.

Franke, A., Hampe, J., Rosenstiel, P., Becker, C., Wagner, F., Hasler, R., Little, R.D., Huse, K., Ruether, A., Balschun, T., *et al.* (2007) Systematic association mapping identifies NELL1 as a novel IBD disease gene. *PLoS ONE.*, 2, e691.

Friedman, S. (2006) Cancer in Crohn's Disease. *Gastroenterology Clinics of North America*, 35, 621-639.

Friedrichs, F., Brescianini, S., Annese, V., Latiano, A., Berger, K., Kugathasan, S., Broeckel, U., Nikolaus, S., Daly, M., Schreiber, S., *et al.* (2006) Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. *Human Genetics*, 119, 305-311.

G

Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., *et al.* (2002) The Structure of Haplotype Blocks in the Human Genome. *Science*, 296, 2225-2229.

Garcia Rodriguez, L.A., Gonzalez-Perez, A., Johansson, S. and Wallander, M.A. (2005) Risk factors for inflammatory bowel disease in the general population. *Alimentary Pharmacology & Therapeutics*, 22, 309-315.

Garnier, S., Dieude, P., Michou, L., Barbet, S., Tan, A., Lasbleiz, S., Bardin, T., Prum, B. and Cornelis, F. (2006) The systemic lupus erythematosus new genetic factor IRF5 rs2004640-T allele is not linked to, nor associated with rheumatoid arthritis, in a family-based study from the French caucasian population. *Ann Rheum Dis*, ard.2006.061390.

Gary, R.L., Songkai, Y., Mohan, B., Marion, B. and Bruce, E.S. (2005) Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. *Gastroenterology*, 128, 862-869.

Gasche C, S.J., Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, and Rachmilewitz D, S.D., Sandborn WJ, Sutherland LR. (2000) A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm. Bowel Dis.*, 6, 8-15.

Girardin, S.E., Travassos, L.H., Herve, M., Blanot, D., Boneca, I.G., Philpott, D.J., Sansonetti, P.J. and Mengin-Lecreulx, D. (2003) Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. *J Biol Chem.*, 278, 41702-41708.

Gonzalez, E., Kulkarni, H., Bolivar, H., Mangano, A., Sanchez, R., Catano, G., Nibbs, R.J., Freedman, B.I., Quinones, M.P., Bamshad, M.J., *et al.* (2005) The Influence of CCL3L1 Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility. *Science*, 307, 1434-1440.

Graham, D.S.C., Manku, H., Wagner, S., Reid, J., Timms, K., Gutin, A., Lanchbury, J.S. and Vyse, T.J. (2007a) Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. *Hum. Mol. Genet.*, 16, 579-591.

Graham, R.R., Kozyrev, S.V., Baechler, E.C., Reddy, M.V.P.L., Plenge, R.M., Bauer, J.W., Ortmann, W.A., Koeuth, T., Escribano, M.F.G., Collaborative Group the Argentine and, S., *et al.* (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. *Nat Genet*, 38, 550-555.

Graham, R.R., Kyogoku, C., Sigurdsson, S., Vlasova, I.A., Davies, L.R., Baechler, E.C., Plenge, R.M., Koeuth, T., Ortmann, W.A., Hom, G., *et al.* (2007b) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. *Proc Natl Acad Sci U S A.*, 104, 6758-6763.

Guyatt, G., Mitchell, A., Irvine, E.J., Singer, J., Williams, N., Goodacre, R. and Tompkins, C. (1989) A new measure of health status for clinical trials in inflammatory bowel disease. *Gastroenterology.*, 96, 804-810.

H

Halfvarson, J., Bodin, L., Tysk, C., Lindberg, E. and Jarnerot, G. (2003) Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. *Gastroenterology.*, 124, 1767-1773.

Halfvarson, J., Jess, T., Magnuson, A., Montgomery, S.M., Orholm, M., Tysk, C., Binder, V. and Jarnerot, G. (2006) Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. *Inflamm Bowel Dis.*, 12, 925-933.

Hampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K., Albrecht, M., Mayr, G., De La Vega, F.M., Briggs, J., *et al.* (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet*, 39, 207-211.

Heinemeyer, T., Wingender, E., Reuter, I., Hermjakob, H., Kel, A. E., Kel, O. V., Ignatieva, E. V., Ananko, E. A., Podkolodnaya, O. A., Kolpakov, F. A., Podkolodny N. L. and Kolchanov, N. A. (1998) Databases on Transcriptional Regulation: TRANSFAC, TRRD, and COMPEL. *Nucleic Acids Res.*, 26, 364-370.

Heresbach, D., Gicquel-Douabin, V., Birebent, B., D'Halluin P, N., Heresbach-Le Berre, N., Dreano, S., Siproudhis, L., Dabadie, A., Gosselin, M., Mosser, J., *et al.* (2004) NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype-phenotype analysis. *Eur J Gastroenterol Hepatol.*, 16, 55-62.

Hiroki, M., Takahiko, H., Nobuaki, H., Hiroshi, T., Shin-Ichi, H., Yuji, K., Junji, O., Seiichi, O., Shigeru, F. and Mine, H. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. *Gastroenterology*, 128, 376-392.

Hlavaty, T., Ferrante, M., Henckaerts, L., Pierik, M., Rutgeerts, P. and Vermeire, S. (2007) Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. *Inflammatory Bowel Diseases*, 13, 372-379.

Hlavaty, T., Pierik, M., Henckaerts, L., Ferrante, M., Joossens, S., Schuerbeek, N., Noman, M., Rutgeerts, P. and Vermeire, S. (2005) Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. *Alimentary Pharmacology & Therapeutics*, 22, 613-626.

Ho, G.-T., Nimmo, E., R. , Tenesa, A., Fennell, J., Drummond, H., Mowat, C., Arnott, I., D. and Satsangi, J. (2005) Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. *Gastroenterology*, 128, 288-296.

Höhler, T., Kruger, A., Gerken, G., Schneider, P.M., Meyer, K.-H. and Rittner, C. (1998) Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. *Journal of Medical Virology*, 54, 173-177.

Hoie, O., Wolters, F., Riis, L., Aamodt, G., Solberg, C., Bernklev, T., Odes, S., Mouzas, I.A., Beltrami, M., Langholz, E., *et al.* Ulcerative Colitis: Patient Characteristics May Predict 10-Yr Disease Recurrence in a European-Wide Population-Based Cohort. *The American Journal of Gastroenterology*, 102, 1692-701

Houghton, E.A. and Naish, J.M. (1958) Familial ulcerative colitis and ileitis. *Gastroenterologia.*, 89, 65-74.

Hsu, T.M., Chen, X., Duan, S., Miller, R.D. and Kwok, P.Y. (2001) Universal SNP genotyping assay with fluorescence polarization detection. *Biotechniques.*, 31, 560, 562, 564-568.

Hugot, J.-P. (2006) CARD15/NOD2 Mutations in Crohn's Disease. *Ann NY Acad Sci*, 1072, 9-18.

Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C.A., Gassull, M., *et al.* (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*, 411, 599-603.

Hugot, J.-P., Laurent-Puig, P., Gower-Rousseau, C., Olson, J.M., Lee, J.C., Beaugerie, L., Naom, I., Dupas, J.-L., Van Gossum, A., Orholm, M., *et al.* (1996) Mapping of a susceptibility locus for Crohn's disease on chromosome 16. *Nature*, 379, 821-823.

Hugot, J.-P., Zaccaria, I., Cavanaugh, J., Yang, H., Vermeire, S., Lappalainen, M., Schreiber, S., Annese, V., Jewell, D.P., Fowler, E.V., *et al.* (2007) Prevalence of CARD15/NOD2 Mutations in Caucasian Healthy People. *The American Journal of Gastroenterology*, 102, 1259-1267.

Hugot, J.P., Alberti, C., Berrebi, D., Bingen, E. and Cezard, J.P. (2003) Crohn's disease: the cold chain hypothesis. *Lancet.*, 362, 2012-2015.

I

Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., Fukase, K., Inamura, S., Kusumoto, S., Hashimoto, M., *et al.* (2003) Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2. IMPLICATIONS FOR CROHN'S DISEASE. *J. Biol. Chem.*, 278, 5509-5512.

J

Jan, M.H.V.d.B., Henri, B., Gijs, R.v.d.B., Henri, H.V., Christiaan, A.B., Inge, H., Catherine van, M., Daan, W.H., Maikel, P.P. and Sander, J.H.v.D. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. *Gastroenterology*, 124, 1774-1785.

Johnson, G.C.L., Esposito, L., Barratt, B.J., Smith, A.N., Heward, J., Di Genova, G., Ueda, H., Cordell, H.J., Eaves, I.A., Dudbridge, F., *et al.* (2001) Haplotype tagging for the identification of common disease genes. *Nat Genet*, 29, 233-237.

K

Kaijzel, E.L., van Krugten, M.V., Brinkman, B.M., Huizinga, T.W., van der Straaten, T., Hazes, J.M., Ziegler-Heitbrock, H.W., Nedospasov, S.A., Breedveld, F.C. and Verweij, C.L. (1998) Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. *Mol Med.*, 4, 724-733.

Karban, A. and Eliakim, R. (2007) Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? *World J Gastroenterol.*, 13, 2150-2152.

Karpova, A.Y., Ronco, L.V. and Howley, P.M. (2001) Functional Characterization of Interferon Regulatory Factor 3a (IRF-3a), an Alternative Splice Isoform of IRF-3. *Mol. Cell. Biol.*, 21, 4169-4176.

Kashi, Y. and King, D.G. (2006) Simple sequence repeats as advantageous mutators in evolution. *Trends Genet.*, 22, 253-259.

Kavvoura, F.K., Akamizu, T., Awata, T., Ban, Y., Chistiakov, D.A., Frydecka, I., Ghaderi, A., Gough, S.C., Hiromatsu, Y., Ploski, R., *et al.* (2007) CTLA-4 Gene Polymorphisms and Autoimmune Thyroid Disease: A Meta Analysis. *J Clin Endocrinol Metab*, jc.2007-0147.

Koelewijn, C., Schrijvers, A. and Oldenburg, B. (2006) Infliximab use in patients with Crohn's disease: quality of life, costs and resource use. *Neth J Med.*, 64, 212-218.

Kontoyiannis, D., Pasparakis, M., Pizarro, T.T., Cominelli, F. and Kollias, G. (1999) Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements: Implications for Joint and Gut-Associated Immunopathologies. *Immunity*, 10, 387-398.

Kuhbacher, T. and Folsch, U.R. (2007) Practical guidelines for the treatment of inflammatory bowel disease. *World J Gastroenterol.*, 13, 1149-1155.

Kuster, W., Pascoe, L., Purrmann, J., Funk, S. and Majewski, F. (1989) The genetics of Crohn disease: complex segregation analysis of a family study with 265 patients with Crohn disease and 5,387 relatives. *Am J Med Genet.*, 32, 105-108.

L

Lakatos, P.L., Fischer, S., Lakatos, L., Gal, I. and Papp, J. (2006) Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? *World J Gastroenterol.*, 12, 1829-1841.

Lander, E.S. (2001) Initial sequencing and analysis of the human genome. *Nature*, 409, 860-921.

Lee, Y.H., Rho, Y.H., Choi, S.J., Ji, J.D., Song, G.G., Nath, S.K. and Harley, J.B. (2007) The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. *Rheumatology*, 46, 49-56.

Lesage, S., Zouali, H., Cezard, J.P., Colombel, J.F., Belaiche, J., Almer, S., Tysk, C., O'Morain, C., Gassull, M., Binder, V., *et al.* (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. *Am J Hum Genet.*, 70, 845-857.

Libioulle, C., Louis, E., Hansoul, S., Sandor, C., Farnir, F., Franchimont, D., Vermeire, S., Dewit, O., de Vos, M., Dixon, A., *et al.* (2007) Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4. *PLoS Genet.*, 3, e58.

Ljung, T., Karlen, P., Schmidt, D., Hellstrom, P.M., Lapidus, A., Janczewska, I., Sjoqvist, U. and Lofberg, R. (2004) Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. *Gut*, 53, 849-853.

Locke, D.P., Sharp, A.J., McCarroll, S.A., McGrath, S.D., Newman, T.L., Cheng, Z., Schwartz, S., Albertson, D.G., Pinkel, D., Altshuler, D.M., *et al.* (2006) Linkage Disequilibrium and Heritability of Copy-Number Polymorphisms within Duplicated Regions of the Human Genome. *Am J Hum Genet.*, 79, 275-290.

Loftus, E.V. (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. *Gastroenterology*, 126, 1504-1517.

Louis, Franchimont, Piron, Gevaert, Schaaf, L., Roland, Mahieu, Malaise, Groote, D.E., Louis, *et al.* (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF- α ; production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. *Clinical & Experimental Immunology*, 113, 401-406.

Louis, E., Collard, A., Oger, A.F., Degroote, E., El Yafi, F.A.N. and Belaiche, J. (2001) Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. *Gut*, 49, 777-782.

Louis, E., El Ghouli, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J.F., *et al.* (2004) Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. *Alimentary Pharmacology & Therapeutics*, 19, 511-519.

Louis, E.J., Watier, H.E., Schreiber, S., Hampe, J., Taillard, F., Olson, A., Thorne, N., Zhang, H. and Colombel, J.F. (2006) Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. *Pharmacogenet Genomics*, 16, 911-914.

Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W. and Kucharzik, T. (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. *Gastroenterology*, 121, 1145-1157.

M

Mancl, M.E., Hu, G., Sangster-Guity, N., Olshalsky, S.L., Hoops, K., Fitzgerald-Bocarsly, P., Pitha, P.M., Pinder, K. and Barnes, B.J. (2005) Two Discrete Promoters Regulate the Alternatively Spliced Human Interferon Regulatory Factor-5 Isoforms: MULTIPLE ISOFORMS WITH DISTINCT CELL TYPE-SPECIFIC EXPRESSION, LOCALIZATION, REGULATION, AND FUNCTION. *J. Biol. Chem.*, 280, 21078-21090.

Marron, M.P., Raffel, L.J., Garchon, H.J., Jacob, C.O., Serrano-Rios, M., Martinez Larrad, M.T., Teng, W.P., Park, Y., Zhang, Z.X., Goldstein, D.R., *et al.* (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. *Hum. Mol. Genet.*, 6, 1275-1282.

Martinez, A., Salido, M., Bonilla, G., Pascual-Salcedo, D., Fernandez-Arquero, M., de Miguel, S., Balsa, A., de la Concha, E. and Fernandez-Gutierrez, B. (2004) Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. *Arthritis & Rheumatism*, 50, 1077-1082.

Mascheretti, S., Hampe, J., Croucher, P.J., Nikolaus, S., Andus, T., Schubert, S., Olson, A., Bao, W., Folsch, U.R. and Schreiber, S. (2002a) Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. *Pharmacogenetics.*, 12, 509-515.

Mascheretti, S., Hampe, J., Kuhbacher, T., Herfarth, H., Krawczak, M., Folsch, U.R. and Schreiber, S. (2002b) Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. *Pharmacogenomics J.*, 2, 127-136.

Mascheretti, S. and Schreiber, S. (2004) The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn s disease. *Pharmacogenomics*, 5, 479-486.

McAlexander, M.B. and Yu-Lee, L.-y. (2001) Sp1 is required for prolactin activation of the interferon regulatory factor-1 gene. *Molecular and Cellular Endocrinology*, 184, 135-141.

McCormack, G., Moriarty, D., O'Donoghue, D.P., McCormick, P.A., Sheahan, K. and Baird, A.W. (2001) Tissue cytokine and chemokine expression in inflammatory bowel disease. *Inflammation Research*, 50, 491-495.

McGovern, D.P.B., Hysi, P., Ahmad, T., van Heel, D.A., Moffatt, M.F., Carey, A., Cookson, W.O.C. and Jewell, D.P. (2005) Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. *Hum. Mol. Genet.*, 14, 1245-1250.

McGuire, W., Hill, A.V.S., Allsopp, C.E.M., Greenwood, B.M. and Kwiatkowski, D. (1994) Variation in the TNF-[alpha] promoter region associated with susceptibility to cerebral malaria. *Nature*, 371, 508-511.

Meucci, G., Vecchi, M., Torgano, G., Arrigoni, M., Prada, A., Rocca, F., Curzio, M., Pera, A. and de Franchis, R. (1992) Familial aggregation of inflammatory bowel disease in northern Italy: a multicenter study. The Gruppo di Studio per le Malattie Infiammatorie Intestinali (IBD Study Group). *Gastroenterology.*, 103, 514-519.

Mills, R.E., Luttig, C.T., Larkins, C.E., Beauchamp, A., Tsui, C., Pittard, W.S. and Devine, S.E. (2006) An initial map of insertion and deletion (INDEL) variation in the human genome. *Genome Res.*, 16, 1182-1190.

Moss, M.L., Jin, S.L.C., Becherer, J.D., Bickett, D.M., Burkhart, W., Chen, W.J., Hassler, D., Leesnitzer, M.T., McGeehan, G., Milla, M., *et al.* (1997) Structural features and biochemical properties of TNF- α converting enzyme (TACE). *Journal of neuroimmunology*, 72, 127-129.

N

Nagamu, I., Kazuo, T., Yoshitaka, K., Yoshihiro, F., Seiichi, T., Yasunori, O., Naohiro, I., Gabriel, N., Yusuke, K., Yuji, K., *et al.* (2002) Lack of common NOD2 variants in Japanese patients with Crohn's disease. *Gastroenterology*, 123, 86-91.

Netea, M.G., Ferwerda, G., de Jong, D.J., Jansen, T., Jacobs, L., Kramer, M., Naber, T.H.J., Drenth, J.P.H., Girardin, S.E., Jan Kullberg, B., *et al.* (2005) Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release. *J Immunol*, 174, 6518-6523.

Newman, B., Gu, X., Wintle, R., Cescon, D., Yazdanpanah, M., Liu, X., Peltekova, V., van, O., Mark, A., Amos, C. and Siminovitch, K. (2005) A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. *Gastroenterology*, 128, 260-269.

Nilsen, E.M., Johansen, F.E., Jahnsen, F.L., Lundin, K.E.A., Scholz, T., Brandtzaeg, P. and Haraldsen, G. (1998) Cytokine profiles of cultured microvascular endothelial cells from the human intestine. *Gut*, 42, 635-642.

Nistico, L., Buzzetti, R., Pritchard, L.E., Van der Auwera, B., Giovannini, C., Bosi, E., Larrad, M.T., Rios, M.S., Chow, C.C., Cockram, C.S., *et al.* (1996) The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. *Hum. Mol. Genet.*, 5, 1075-1080.

O

Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R.H., *et al.* (2001a) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature*, 411, 603-606.

Ogura, Y., Inohara, N., Benito, A., Chen, F.F., Yamaoka, S. and Nunez, G. (2001b) Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-kappa B. *J. Biol. Chem.*, 276, 4812-4818.

Ohmen, J.D., Yang, H.Y., Yamamoto, K.K., Zhao, H.Y., Ma, Y., Bentley, L.G., Huang, Z., Gerwehr, S., Pressman, S., McElree, C., *et al.* (1996) Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. *Hum. Mol. Genet.*, 5, 1679-1683.

Orholm, M., Binder, V., Sorensen, T.I., Rasmussen, L.P. and Kyvik, K.O. (2000) Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. *Scand J Gastroenterol.*, 35, 1075-1081.

Orholm, M., Munkholm, P., Langholz, E., Nielsen, O.H., Sorensen, T.I. and Binder, V. (1991) Familial occurrence of inflammatory bowel disease. *N Engl J Med.*, 324, 84-88.

Otley, A. and Steinhart, A.H. (2005) Budesonide for induction of remission in Crohn's disease. *Cochrane Database Syst Rev.*

Ouyang, X., Negishi, H., Takeda, R., Fujita, Y., Taniguchi, T. and Honda, K. (2007) Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5\par activation. *Biochem Biophys Res Commun.*, 354, 1045-1051.

Ozeki, T., Furuya, Y., Nagano, C., Matsui, C., Takayanagi, R., Yokoyama, H. and Yamada, Y. (2006) Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients. *Mutat Res.*, 602, 170-174.

P

Pasare, C. and Medzhitov, R. (2004) Toll-like receptors: linking innate and adaptive immunity. *Microbes Infect.*, 6, 1382-1387.

Peltekova, V.D., Wintle, R.F., Rubin, L.A., Amos, C.I., Huang, Q., Gu, X., Newman, B., Oene, M.V., Cescon, D., Greenberg, G., *et al.* (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. *Nat Genet*, 36, 471-475.

Pierik, M., Rutgeerts, P., Vlietinck, R. and Vermeire, S. (2006) Pharmacogenetics in inflammatory bowel disease. *World J Gastroenterol.*, 12, 3657-3667.

Pierik, M., Vermeire, S., Steen, K.V., Joossens, S., Claessens, G., Vlietinck, R. and Rutgeerts, P. (2004) Tumour necrosis factor; receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. *Alimentary Pharmacology & Therapeutics*, 20, 303-310.

Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezaand, R.A., Podolsky, D.K., Sands, B.E., Braakman, T., DeWoody, K.L., *et al.* (1999) Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease. *N Engl J Med*, 340, 1398-1405.

Probert, C.S., Jayanthi, V., Hughes, A.O., Thompson, J.R., Wicks, A.C. and Mayberry, J.F. (1993) Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. *Gut.*, 34, 1547-1551.

R

Radford-Smith, G. and Pandeya, N. (2006) Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease--Are we there yet? *World J Gastroenterol.*, 12, 7097-7103.

Radford-Smith, G.L., Edwards, J.E., Purdie, D.M., Pandeya, N., Watson, M., Martin, N.G., Green, A., Newman, B. and Florin, T.H. (2002) Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. *Gut.*, 51, 808-813.

Redon, R., Ishikawa, S., Fitch, K.R., Feuk, L., Perry, G.H., Andrews, T.D., Fiegler, H., Shapero, M.H., Carson, A.R., Chen, W., *et al.* (2006) Global variation in copy number in the human genome. *Nature*, 444, 444-454.

Ringheanu, M., Daum, F., Markowitz, J., Levine, J., Katz, S., Lin, X. and Silver, J. (2004) Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. *Inflamm Bowel Dis.*, 10, 801-810.

Robinson, D., Hackett, M., Wong, J., Kimball, A.B., Cohen, R., Bala, M. and The, I.S.G. (2006) Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 20012002. *Current Medical Research and Opinion*, 22, 989-1000.

Rodriguez-Reventa, L., Mila, M., Rosenberg, C., Lamb, A. and Lee, C. (2007) Structural variation in the human genome: the impact of copy number variants on clinical diagnosis. *Genet Med.*, 9, 600-606.

Rossol, M., Meusch, U., Pierer, M., Kaltenhauser, S., Hantzschel, H., Hauschildt, S. and Wagner, U. (2007) Interaction between Transmembrane TNF and TNFR1/2 Mediates the Activation of Monocytes by Contact with T Cells. *J Immunol*, 179, 4239-4248.

Rothfuss, K.S., Stange, E.F. and Herrlinger, K.R. (2006) Extraintestinal manifestations and complications in inflammatory bowel diseases. *World J Gastroenterol.*, 12, 4819-4831.

Russel, M.G., Dorant, E., Brummer, R.J., van de Kruijs, M.A., Muris, J.W., Bergers, J.M., Goedhard, J. and Stockbrugger, R.W. (1997) Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: Results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. *Gastroenterology*, 113, 377-382.

S

Satsangi, J., Grootcholten, C., Holt, H. and Jewell, D.P. (1996) Clinical patterns of familial inflammatory bowel disease. *Gut*, 38, 738-741

Scheet, P. and Stephens, M. (2006) A Fast and Flexible Statistical Model for Large-Scale Population Genotype Data: Applications to Inferring Missing Genotypes and Haplotype Phase. *Am J Hum Genet*, 78, 629-644.

Schreiber, S., Rosenstiel, P., Albrecht, M., Hampe, J. and Krawczak, M. (2005) GENETICS OF CROHN DISEASE, AN ARCHETYPAL INFLAMMATORY BARRIER DISEASE. *Nature Reviews Genetics*, 6, 376-388.

Sechi, L.A., Manuela, M., Francesco, T., Amelia, L., Antonello, S., Giovanni, F. and Stefania, Z. (2001) Identification of Mycobacterium avium subsp. paratuberculosis in Biopsy Specimens from Patients with Crohn's Disease Identified by In Situ Hybridization. *J. Clin. Microbiol.*, 39, 4514-4517.

Sharma, S., Grandvaux, N., Mamane, Y., Genin, P., Azimi, N., Waldmann, T. and Hiscott, J. (2002) Regulation of IFN Regulatory Factor 4 Expression in Human T Cell Leukemia Virus-I-Transformed T Cells. *J Immunol*, 169, 3120-3130.

Sigurdsson, S., Nordmark, G., Goring, H.H., Lindroos, K., Wiman, A.C., Sturfelt, G., Jonsen, A., Rantapaa-Dahlqvist, S., Moller, B., Kere, J., *et al.* (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. *Am J Hum Genet.*, 76, 528-537.

Sigurdsson, S., Padyukov, L., Kurreeman, F.A.S., Liljedahl, U., Wiman, A.-C., Alfredsson, L., Toes, R., Rönnelid, J., Klareskog, L., Huizinga, T.W.J., *et al.* (2007) Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. *Arthr Rheum* 56, 2202-2210.

Sostegni, R.p., Daperno, M.p., Scaglione, N.p., Lavagna, A.p., Rocca, R.p. and Pera, A.p. (2003) Review article: Crohn's disease: monitoring disease activity. *Aliment Pharmacol Ther.*, 17, 11-17.

Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T.T., *et al.* (2002) Neuregulin 1 and susceptibility to schizophrenia. *Am J Hum Genet.*, 71, 877-892.

Stephens, M. and Scheet, P. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. *Am J Hum Genet.*, 76, 449-462.

Stephens, M., Smith, N.J. and Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet.*, 68, 978-989.

Stoll, M., Corneliussen, B., Costello, C.M., Waetzig, G.H., Mellgard, B., Koch, W.A., Rosenstiel, P., Albrecht, M., Croucher, P.J.P., Seegert, D., *et al.* (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. *Nat Genet*, 36, 476-480.

Su, C. and Lichtenstein, G.R. (2005) Are there predictors of Remicade treatment success or failure? *Adv Drug Deliv Rev.*, 57, 237-245.

Suenaert, P., Bulteel, V., Lemmens, L., Noman, M., Geypens, B., Assche, G.V., Geboes, K., Ceuppens, J.L. and Rutgeerts, P. (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. *The American Journal of Gastroenterology*, 97, 2000-2004.

T

Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Kano, S.-i., Honda, K., Ohba, Y., Mak, T.W., *et al.* (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. *Nature*, 434, 243-249.

Tang, P., Hung, M.C. and Klostergaard, J. (1996) Human pro-Tumor Necrosis Factor Is a Homotrimer. *Biochemistry*, 35, 8216-8225.

Targan, S.R., Hanauer, S.B., van Deventer, S.J.H., Mayer, L., Present, D.H., Braakman, T., DeWoody, K.L., Schaible, T.F., Rutgeerts, P.J. and The Crohn's Disease c, A.S.G. (1997) A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor {alpha} for Crohn's Disease. *N Engl J Med*, 337, 1029-1036.

Taylor, K.D., Plevy, S., Yang, H., Landers, C., Barry, M., Rotter, J. and Targan, S. (2001) ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. *Gastroenterology*, 120, 1347-1355.

The International HapMap, C. (2005) A haplotype map of the human genome. *Nature*, 437, 1299-1320.

Thompson, N.P., Driscoll, R., Pounder, R.E. and Wakefield, A.J. (1996) Genetics versus environment in inflammatory bowel disease: results of a British twin study. *Bmj.*, 312, 95-96.

Tilg, H., Moschen, A. and Kaser, A. (2007) Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. *Expert Opinion on Biological Therapy*, 7, 1051-1059.

Torikai, E., Kageyama, Y., Suzuki, M., Ichikawa, T. and Nagano, A. (2007) The effect of infliximab on chemokines in patients with rheumatoid arthritis. *Clinical Rheumatology*, 26, 1088-1093.

Tremelling, M., Cummings, F., Fisher, S.A., Mansfield, J., Gwilliam, R., Keniry, A., Nimmo, E.R., Drummond, H., Onnie, C.M., Prescott, N.J., *et al.* (2007) IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. *Gastroenterology*, 132, 1657-1664.

Tysk, C., Lindberg, E., Jarnerot, G. and Floderus-Myrhed, B. (1988) Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. *Gut*, 29, 990-996.

V

van den Brande, J., Hommes, D.W. and Peppelenbosch, M.P. (2005) Infliximab induced T lymphocyte apoptosis in Crohn's disease. *J Rheumatol Suppl.*, 74, 26-30.

Van den Brande, J.M.H., Koehler, T.C., Zelinkova, Z., Bennink, R.J., te Velde, A.A., ten Cate, F.J.W., van Deventer, S.J.H., Peppelenbosch, M.P. and Hommes, D.W. (2007) Prediction of antitumor necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. *Gut*, 56, 509-517.

van Dullemen, H.M., van Deventer, S.J., Hommes, D.W., Bijl, H.A., Jansen, J., Tytgat, G.N. and Woody, J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). *Gastroenterology*, 109, 129-135.

Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., *et al.* (2001) The Sequence of the Human Genome. *Science*, 291, 1304-1351.

W

Wang, D.G., Fan, J.-B., Siao, C.-J., Berno, A., Young, P., Sapolsky, R., Ghandour, G., Perkins, N., Winchester, E., Spencer, J., *et al.* (1998) Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome. *Science*, 280, 1077-1082.

Ware, C.F., VanArsdale, T.L., Crowe, P.D. and Browning, J.L. (1995) The ligands and receptors of the lymphotoxin system. *Curr Top Microbiol Immunol.*, 198, 175-218.

Watts, A.D., Hunt, N.H., Madigan, M.C. and Chaudhri, G. (1999) Soluble TNF-alpha receptors bind and neutralize over-expressed transmembrane TNF-alpha on macrophages, but do not inhibit its processing. *J Leukoc Biol*, 66, 1005-1013.

Weng, X., Liu, L., Barcellos, L.F., Allison, J.E. and Herrinton, L.J. Clustering of Inflammatory Bowel Disease With Immune Mediated Diseases Among Members of a Northern California-Managed Care Organization. *The American Journal of Gastroenterology*, 102, 1429 - 35

Wilks, S. (1859) Morbid appearances in the intestine of Miss Bankes. *London Medical Gazette*, 2, 264.

Wilks S, M.W. (1875) Lectures on Pathological Anatomy. 2nd Ed. Philadelphia Lindsay and Blakiston.

Willot, S., Vermeire, S., Ohresser, M., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Franchimont, D., Colombel, J.F., *et al.* (2006) No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. *Pharmacogenet Genomics.*, 16, 37-42.

Wojciech Blonski, G.R.L. (2007) Safety of biologic therapy. *Inflammatory Bowel Diseases*, 13, 769-796.

Y

Yamamoto-Furusho, J.K. and Korzenik, J.R. (2006) Crohn's disease: innate immunodeficiency? *World J Gastroenterol.*, 12, 6751-6755.

Yamazaki, K., McGovern, D., Ragoussis, J., Paolucci, M., Butler, H., Jewell, D., Cardon, L., Takazoe, M., Tanaka, T., Ichimori, T., *et al.* (2005) Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. *Hum. Mol. Genet.*, 14, 3499-3506.

Yang, Y., Chung, E.K., Wu, Y.L., Savelli, S.L., Nagaraja, H.N., Zhou, B., Hebert, M., Jones, K.N., Shu, Y., Kitzmiller, K., *et al.* (2007) Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. *Am J Hum Genet.*, 80, 1037-1054.

Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M.A., Owyang, A., Mattson, J., Blumenschein, W., *et al.* (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. *J. Clin. Invest.*, 116, 1310-1316.

Z

Zeissig, S., Bojarski, C., Buergel, N., Mankertz, J., Zeitz, M., Fromm, M. and Schulzke, J.D. (2004) Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor {alpha} antibody treatment. *Gut*, 53, 1295-1302.